Annovis Bio/ANVS

$11.14

-4.21%
-
1D1W1MYTD1YMAX

About Annovis Bio

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.

Ticker

ANVS

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Maria Maccecchini

Employees

6

Headquarters

Malvern, United States

Annovis Bio Metrics

BasicAdvanced
$128.06M
Market cap
-
P/E ratio
-$6.12
EPS
1.60
Beta
-
Dividend rate
$128.06M
1.59729
$22.49
$5.42
239.02K
2.386
-4.03%
-243.15%
-546.4%
-328.17%
-141.54%

What the Analysts think about Annovis Bio

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
217.77% upside
High $72.00
Low $13.00
$11.14
Current price
$35.40
Average price target

Annovis Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-22.2M
51.02%
Profit margin
0%
-

Annovis Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 71.71%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.19
-$1.07
-$1.63
-$2.24
-
Expected
-$0.33
-$1.14
-$1.09
-$1.30
-$0.69
Surprise
256.29%
-6.28%
49.5%
71.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Annovis Bio stock?

Annovis Bio (ANVS) has a market cap of $128.06M as of April 15, 2024.

What is the P/E ratio for Annovis Bio stock?

The price to earnings (P/E) ratio for Annovis Bio (ANVS) stock is 0 as of April 15, 2024.

Does Annovis Bio stock pay dividends?

No, Annovis Bio (ANVS) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Annovis Bio dividend payment date?

Annovis Bio (ANVS) stock does not pay dividends to its shareholders.

What is the beta indicator for Annovis Bio?

Annovis Bio (ANVS) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Annovis Bio stock price target?

The target price for Annovis Bio (ANVS) stock is $35.4, which is 217.77% above the current price of $11.14. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Annovis Bio stock

Buy or sell Annovis Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing